We determined RNA and protein levels of BCL-2 family members in large cohorts of TP53-mutant AML and investigated if shifting the balance of BCL-2 proteins to pro-death by co-targeting BCL-2 and MCL-1 could overcome TP53-mutant AML resistance to individual BH3 mimetics. The gene discussed is BCL2; the disease is acute myeloid leukemia.